DK0590428T3 - Azaquinoxaliner, fremgangsmåde til deres fremstilling og deres anvendelse - Google Patents

Azaquinoxaliner, fremgangsmåde til deres fremstilling og deres anvendelse

Info

Publication number
DK0590428T3
DK0590428T3 DK93114934T DK93114934T DK0590428T3 DK 0590428 T3 DK0590428 T3 DK 0590428T3 DK 93114934 T DK93114934 T DK 93114934T DK 93114934 T DK93114934 T DK 93114934T DK 0590428 T3 DK0590428 T3 DK 0590428T3
Authority
DK
Denmark
Prior art keywords
azaquinoxalins
preparation
methods
formula
image
Prior art date
Application number
DK93114934T
Other languages
Danish (da)
English (en)
Inventor
Uta-Maria Billhardt-Troughton
Manfred Dr Roesner
Rudolf Dr Bender
Christoph Dr Meichsner
Original Assignee
Hoechst Ag
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag, Aventis Pharma Gmbh filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK0590428T3 publication Critical patent/DK0590428T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK93114934T 1992-09-26 1993-09-16 Azaquinoxaliner, fremgangsmåde til deres fremstilling og deres anvendelse DK0590428T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4232392 1992-09-26

Publications (1)

Publication Number Publication Date
DK0590428T3 true DK0590428T3 (da) 2000-05-22

Family

ID=6468974

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93114934T DK0590428T3 (da) 1992-09-26 1993-09-16 Azaquinoxaliner, fremgangsmåde til deres fremstilling og deres anvendelse

Country Status (20)

Country Link
US (1) US5424311A (ro)
EP (1) EP0590428B1 (ro)
JP (1) JPH06211855A (ro)
KR (1) KR940007035A (ro)
AT (1) ATE187724T1 (ro)
AU (1) AU664643B2 (ro)
CA (1) CA2106882C (ro)
CZ (1) CZ9302005A3 (ro)
DE (1) DE59309902D1 (ro)
DK (1) DK0590428T3 (ro)
ES (1) ES2141744T3 (ro)
GR (1) GR3032520T3 (ro)
HU (1) HUT65302A (ro)
IL (1) IL107081A (ro)
MX (1) MX9305894A (ro)
NZ (1) NZ248762A (ro)
PH (1) PH30348A (ro)
PT (1) PT590428E (ro)
TW (1) TW274550B (ro)
ZA (1) ZA937081B (ro)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1599395A (en) * 1994-01-03 1995-08-01 Cocensys, Inc. 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
US5801183A (en) * 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
US5646130A (en) * 1995-06-30 1997-07-08 Ocean University Of Oingdao Low molecular weight sulfated polysaccharides and uses thereof
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
EP1037590B1 (en) 1998-07-16 2004-04-14 Aaron Tabor Soy formulations and their use for promoting health
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
AU2003220401A1 (en) 2002-03-18 2003-10-08 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
WO2004104003A1 (de) * 2003-05-23 2004-12-02 Zentaris Gmbh Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP2013208B1 (en) * 2006-04-21 2011-06-22 Pfizer Products Inc. Pyridin[3,4-b]pyrazinones
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
GB0614471D0 (en) * 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
WO2008051494A1 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
BRPI0717767A2 (pt) 2006-10-19 2013-11-12 Signal Pharm Llc Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula de expressa a dita quinase
WO2008063455A1 (en) * 2006-11-13 2008-05-29 Hines Richard A Over-the wire exclusion device and system for delivery
CA2695406A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
TWI480268B (zh) 2008-12-09 2015-04-11 Gilead Sciences Inc 類鐸受體的調節劑
MA33053B1 (fr) 2009-01-23 2012-02-01 Tadeka Pharmaceutical Company Ltd Inhibiteurs de la poly(adp-ribose) polymerase (parp)
WO2011014681A1 (en) 2009-07-30 2011-02-03 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS
SI2477987T1 (en) * 2009-09-14 2018-03-30 Gilead Sciences, Inc. MODULATORS TO TOLL OF LIKE RECEPTORS
CN102686225A (zh) 2009-10-26 2012-09-19 西格诺药品有限公司 杂芳基化合物的合成和纯化方法
UA110697C2 (uk) 2010-02-03 2016-02-10 Сігнал Фармасьютікалз, Елелсі ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EP3466423B1 (en) 2011-10-19 2021-07-28 Signal Pharmaceuticals, LLC Treatment of cancer with tor kinase inhibitors
US9351974B2 (en) 2011-11-10 2016-05-31 OSI Pharmaceuticals, LLC Substituted pteridinones for the treatment of cancer
EP2785325B1 (en) 2011-12-02 2018-08-22 Signal Pharmaceuticals, LLC Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
MX358303B (es) 2012-02-24 2018-08-14 Signal Pharm Llc Uso de 7-(6-(2-hidroxipropan-2il) piridin-3-il)-1-((1r,4r)4-metoxi ciclohexil)-3, 4-dihidropirazin-[2,3-b] pirazin-2(1h)-ona o una sal, estereoisómero o tautómero aceptable farmaceuticamente del mismo, en combinación con una cantidad efectiva de erlotinib o azacitidina para preparar un composición farmacéutica en el tratamiento de cáncer de pulmón de cédula no pequeña, avanzado.
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
PE20151995A1 (es) 2013-01-16 2016-01-13 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos
US9358232B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
AU2014254059B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for treating cancer
JP6382949B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
CN105377299B (zh) 2013-04-17 2018-06-12 西格诺药品有限公司 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
NZ629332A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
NZ629230A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
WO2014172426A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CN113831345A (zh) 2013-05-29 2021-12-24 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
AU2015287773B2 (en) 2014-07-11 2018-03-29 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
JP2017520603A (ja) 2014-07-14 2017-07-27 シグナル ファーマシューティカルズ，エルエルシー 置換ピロロピリミジン化合物を使用するがんの治療方法及びその組成物
WO2016044182A1 (en) 2014-09-16 2016-03-24 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
JP6373490B2 (ja) 2014-09-16 2018-08-15 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターを調製する方法
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
BR112019027402A2 (pt) 2017-06-22 2020-07-07 Celgene Corporation tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b
KR102272284B1 (ko) * 2020-01-13 2021-07-02 금오공과대학교 산학협력단 정밀 압력제어가 가능한 다단 스프링 압력제어밸브

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077955A (en) * 1977-02-17 1978-03-07 E. R. Squibb & Sons, Inc. Amino derivatives of 1,2,3,4-tetrahydro-2-oxopyrido[2,2-b]-pyrazine carboxylic acids and esters
GR72941B (ro) * 1978-10-20 1984-01-16 Lilly Co Eli
IE58312B1 (en) * 1984-05-18 1993-09-08 Union Pharma Scient Appl Heterocyclic derivatives, processes for their preparation and drugs in which they are present, which are useful especially as aldose reductase inhibitors
JPH0276860A (ja) * 1987-10-05 1990-03-16 Toyo Jozo Co Ltd ６−置換アルコキシ−２−オキソ−１，２−ジヒドロキノキサリン誘導体
DK160876C (da) * 1987-12-08 1991-10-14 Novo Nordisk As Imidazoquinoxalinforbindelser, fremgangsmaade til deres fremstilling, anvendelse af forbindelserne og farmaceutiske praeparater, hvori forbindelserne indgaar
DE59209965D1 (de) * 1991-04-15 2002-10-17 Aventis Pharma Gmbh Chinoxaline, Verfahren zu ihrer Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
AU4755393A (en) 1994-03-31
ES2141744T3 (es) 2000-04-01
MX9305894A (es) 1994-03-31
PT590428E (pt) 2000-04-28
CA2106882C (en) 2007-04-17
IL107081A0 (en) 1993-12-28
CA2106882A1 (en) 1994-03-27
KR940007035A (ko) 1994-04-26
NZ248762A (en) 1996-01-26
AU664643B2 (en) 1995-11-23
GR3032520T3 (en) 2000-05-31
EP0590428B1 (de) 1999-12-15
CZ9302005A3 (en) 1994-04-13
ATE187724T1 (de) 2000-01-15
EP0590428A1 (de) 1994-04-06
HUT65302A (en) 1994-05-02
IL107081A (en) 1999-07-14
TW274550B (ro) 1996-04-21
JPH06211855A (ja) 1994-08-02
ZA937081B (en) 1994-04-18
DE59309902D1 (de) 2000-01-20
HU9302696D0 (en) 1993-12-28
US5424311A (en) 1995-06-13
PH30348A (en) 1997-04-02

Similar Documents

Publication Publication Date Title
DK0590428T3 (da) Azaquinoxaliner, fremgangsmåde til deres fremstilling og deres anvendelse
ATE269290T1 (de) Benzoylderivate
BG92804A (bg) 4-бензоилизоксазолови производни
DE59310337D1 (de) 2,4-Dioxo-imidazolidin-Derivate
UA7017A1 (uk) Гербіцидний засіб
DK0519327T3 (da) N-Acyl-S-(2-hydroxyalkyl) -cysteiner, deres fremstilling samt deres anvendelse som mellemprodukter til fremstilling af synt
MX9201760A (es) Quinoxalinas, procedimiento para su preparacion y su empleo.
FI904604A0 (fi) Pyrimidin-4,6 -dikarboxylsyraamider, foerfarande foer deras framstaellning samt deras anvaendning samt pao dessa foereningar baserade laekemedel.
NZ195450A (en) Regulating plant growth with 1-phenoxy-3 3-dimethyl-2-(pyrimidin-5-yl) butan-2-ols
DK0579968T3 (da) 4-Iminoquinoliner, fremgangsmåde til deres fremstilling og deres anvendelse
NO930205D0 (no) Benzimidazoler, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
MX9303605A (es) Derivados de azabicicloheptano n-substituidas, su obtencion y uso.
BG98238A (en) Substituted benzothiazole derivatives, methods for their preparation and their application as herbicides
NO20015202D0 (no) <beta>-hydroksyalkylamider, fremgangsmåte for deres fremstilling og deres anvendelse
ATE92070T1 (de) Azachromanderivate.
BR9916154A (pt) 1 3, 5 triazinas substituìdas
FI960588A0 (fi) Mikrobisideina käytettäviä tiokarbamoyyliyhdisteitä
ATE66921T1 (de) Verwendung von triazolylderivate zur bekaempfung von pilzen.
ES8703855A1 (es) Procedimiento para la obtencion de derivados de sulfonilgua-nidinotriazina
ATE60765T1 (de) Pyranderivate.
ES2054631T3 (es) 1-(2-halogeno-alcoxi-bencenosulfonil)-3-heteroaril-ureas, 3-substituidas.